IDEXX Laboratories (IDXX) investor relations material

Leadership vision and strategic goals

• New CEO emphasizes a purpose-driven approach, focusing on empowering customers through integrated diagnostics and software for deeper insights and productivity gains.

• Innovation is a top priority, with a robust pipeline spanning point-of-care, reference labs, and software.

• Expanding global commercial footprint and customer engagement are key to driving adoption and growth.

• Long-term growth strategy remains transparent and focused on delivering value to customers, employees, and shareholders.

Innovation and technology integration

• AI and software are central to product development, with solutions like inVue Dx and SediVue Dx transforming manual processes and improving efficiency.

• AI adoption extends to internal operations, accelerating software development cycles.

• AI-enabled diagnostics, such as inVue Dx, reduce costs and expand access to care, particularly for cytology and fine needle aspirate (FNA) testing.

• Continuous software and AI enhancements are pushed to connected devices globally, expanding diagnostic capabilities.

Product performance and growth drivers

• inVue Dx launch exceeded expectations, with strong demand and high adoption for ear cytology and blood morphology; FNA launch is in controlled phase, moving to broader rollout later in the year.

• Revenue per inVue Dx unit is already within the projected $3,500–$5,500 range, with further upside as FNA adoption grows.

• Innovation in platforms like Catalyst has historically increased economic value per instrument, a model expected for inVue Dx as well.

• Growth is driven by multiple platforms and innovations, not just inVue Dx, with double-digit growth in point-of-care and reference labs.